Risk for Alzheimer Dementia Lower With Treated Versus Untreated HTN
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 14, 2024 -- Individuals with treated hypertension have a reduced risk for Alzheimer dementia (AD) compared with those with untreated hypertension, according to research published online Aug. 14 in Neurology.
Matthew J. Lennon, M.D., from the University of New South Wales in Sydney, and colleagues examined whether previous hypertension or antihypertensive use modifies AD or non-AD (all-cause dementia) risk in late life in an individual participant data meta-analysis that included community-based longitudinal studies of aging. The risks for developing AD and non-AD were examined as the main outcomes, while the main exposures were hypertension history/antihypertensive use and baseline systolic and diastolic blood pressure (BP). The analysis included 31,250 participants (mean baseline age, 72 years) from 14 nations.
The researchers found that compared with healthy controls and those with treated hypertension, participants with untreated hypertension had a significantly increased risk for AD (hazard ratios, 1.36 and 1.42, respectively). Both those with treated and untreated hypertension had greater non-AD risk compared with healthy controls (hazard ratios, 1.29 and 1.69, respectively), with no difference seen between the treated and untreated groups. In an analysis restricted to those with five-year follow-up, baseline BP had a significant U-shaped relationship with non-AD risk, but there were no other relationships seen between baseline BP and AD or non-AD risk.
"Throughout late life those with treated hypertension had a lower risk of AD compared with those with untreated hypertension, suggesting that antihypertensive use should be part of any AD prevention strategy even in late life," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...
Dementia Risk Does Not Differ With GLP-1 RAs, DPP4is for Seniors With T2DM
MONDAY, July 21, 2025 -- For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.